Towards a new tuberculosis drug: pyridomycin - nature's isoniazid - Wikidata - awgldk - TriplyDB

Towards a new tuberculosis drug: pyridomycin - nature's isoniazid

Towards a new tuberculosis drug: pyridomycin - nature's isoniazid

http://www.wikidata.org/entity/Q27673316

about

New agents for the treatment of drug-resistant Mycobacterium tuberculosis The application of tetracyclineregulated gene expression systems in the validation of novel drug targets in Mycobacterium tuberculosis Whole-genome sequencing targets drug-resistant bacterial infections Next-generation antimicrobials: from chemical biology to first-in-class drugs Tuberculosis drug discovery in the post-post-genomic era Tuberculosis: From an incurable scourge to a curable disease - journey over a millennium A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA Learning from the past for TB drug discovery in the future Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins The Inosine Monophosphate Dehydrogenase, GuaB2, Is a Vulnerable New Bactericidal Drug Target for Tuberculosis.TB Mobile: a mobile app for anti-tuberculosis molecules with known targets Design, synthesis and structure-activity relationship study of wollamide B; a new potential anti TB agent.Discovery of Mycobacterium tuberculosis InhA Inhibitors by Binding Sites Comparison and Ligands Prediction.The Redox State Regulates the Conformation of Rv2466c to Activate the Antitubercular Prodrug TP053.The phosphatidyl-myo-inositol mannosyltransferase PimA is essential for Mycobacterium tuberculosis growth in vitro and in vivo The mycobacterial cell envelope-lipids Lansoprazole is an antituberculous prodrug targeting cytochrome bc1.Systems-level antimicrobial drug and drug synergy discovery.A phylogeny-based sampling strategy and power calculator informs genome-wide associations study design for microbial pathogens.Direct inhibitors of InhA are active against Mycobacterium tuberculosis.Whole-genome sequencing for comparative genomics and de novo genome assembly.The tuberculosis drug discovery and development pipeline and emerging drug targets.Genetic Approaches to Facilitate Antibacterial Drug Development.Computer-Aided Design of Orally Bioavailable Pyrrolidine Carboxamide Inhibitors of Enoyl-Acyl Carrier Protein Reductase of Mycobacterium tuberculosis with Favorable Pharmacokinetic Profiles.Characterization of Mycolic Acids in Total Fatty Acid Methyl Ester Fractions from Mycobacterium Species by High Resolution MALDI-TOFMS.New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics.Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis.Back to the future: a new 'old' lead for tuberculosis.Selectivity of Pyridone- and Diphenyl Ether-Based Inhibitors for the Yersinia pestis FabV Enoyl-ACP Reductase.Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor.Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis.Novel Pharmacological Activity of Artesunate and Artemisinin: Their Potential as Anti-Tubercular Agents.Emerging trends in the discovery of natural product antibacterials.Tuberculosis drug discovery and emerging targets.Trends in discovery of new drugs for tuberculosis therapy.Mycobacterium tuberculosis evolutionary pathogenesis and its putative impact on drug development.Strategies for target identification of antimicrobial natural products.Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis.Synthesis and antimycobacterial activity of 2,1'-dihydropyridomycins

P2860

Q26751463-B3949341-3E2F-4F2A-BE2D-73D75875FEA6 Q26795478-4C3639FF-7805-4F4B-A43C-A435FD429530 Q26799059-21BD39B4-B875-4377-9E85-2CCAE34ED852 Q26799749-BD259905-F25F-4E3C-BAB9-1FC17037A549 Q26864729-D04398F0-3CBB-4BC1-B239-EE110307D379 Q26865560-506AA7ED-52EE-4F37-967E-E729E4C53E6B Q27339306-1C609EC7-F9B3-45CD-8F4D-A6796B2A31D3 Q27485405-142AEB1F-1302-4997-9BFD-6EE06DFACC6F Q27687750-FB47A21C-FE37-4139-82E3-3B985FE567A5 Q27700967-65162371-FA61-4394-B532-3F9B85412FFF Q27728459-1856F031-0CD3-43E2-8CFB-4D15F7582D47 Q28709353-456330C6-9B21-439C-A1D8-B8942ADA94CC Q30313238-033B9C36-ED6C-4E82-9366-FF9F44335D14 Q30396236-CE116597-D7C2-4587-B94B-10A6B979BC99 Q30692645-4578DFEF-D9C1-47EA-8232-00194D27788C Q34297745-1E2E1DB8-08EF-475D-A96A-83BB6F838ED7 Q34355375-EE301B57-D87F-4FED-BAC9-F8D532D7BBBC Q34484243-36B58549-704F-4721-88D8-7F757F5BA65D Q34626969-13507285-F0B2-4895-85FA-16BE1F4CD0D0 Q34636791-C7B4093E-8293-4F9D-85DF-EC4885DC3AA6 Q35247307-ED6928D9-6196-4E8A-935B-6FA186D35B2A Q35579074-A3CACC8D-5177-4B6F-872E-05EBB7F763B4 Q35664209-6C762CE8-7A36-4257-A821-0AF7D746597F Q35795582-B3F0F455-E610-4481-ABB7-F1FD0F752096 Q35878348-507B8658-67FE-4475-9FA6-B03C3A73B26E Q35906843-DD71604B-87E1-41D2-A197-C5AE87970311 Q36057012-DCB1F8B9-8DB1-4A2D-BBF2-F76E3924F83A Q36364079-D223EE33-2E91-4C8A-A0C0-673A022174FE Q36379530-3DAD0CD4-AA56-4048-B394-E85C9FD7253B Q36951981-9F5EC20F-D5C8-4BE2-9B84-CF051D0A062E Q37034701-2B9B751E-6B94-4577-8340-AEBF548972E6 Q37403156-DC7D6498-A661-4E07-8CBA-676F4C0E587B Q37729940-833E557C-9946-48A1-90AF-8A94D291958F Q38124531-861DB892-581B-4AC8-B599-4BFCE2221035 Q38219605-936173F1-6369-44F8-A4E8-582B49D4437A Q38237221-742327A0-9B24-467A-A401-11E9C87D592B Q38258834-B624E6C4-9EE5-4194-9FA6-5FD2E2D9A78C Q38710256-2729A57E-A3E5-4BCF-9763-1008D8F187E9 Q38849126-F3D99176-F0A7-4EAD-BF95-A45D34E0EB0C Q39779898-407ADB14-EA63-4BAA-B88F-240BA2635590

P2860

Towards a new tuberculosis drug: pyridomycin - nature's isoniazid

http://www.wikidata.org/entity/Q27673316

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Towards a new tuberculosis drug: pyridomycin - nature's isoniazid

@ast

Towards a new tuberculosis drug: pyridomycin - nature's isoniazid

@en

Towards a new tuberculosis drug: pyridomycin - nature's isoniazid

@nl

type

label

Towards a new tuberculosis drug: pyridomycin - nature's isoniazid

@ast

Towards a new tuberculosis drug: pyridomycin - nature's isoniazid

@en

Towards a new tuberculosis drug: pyridomycin - nature's isoniazid

@nl

prefLabel

Towards a new tuberculosis drug: pyridomycin - nature's isoniazid

@ast

Towards a new tuberculosis drug: pyridomycin - nature's isoniazid

@en

Towards a new tuberculosis drug: pyridomycin - nature's isoniazid

@nl

P1433

Q27673316-BD06012A-E81A-470A-B1BA-71E9E8E6AC85

P1476

Q27673316-A77F285F-09D1-4D9B-AF30-6E161F72B1E2

P2093

Q27673316-03FAA551-FC43-457F-8F07-2FEE12467D9D

Q27673316-055F44A3-2D2E-43AB-93D6-2370908ECB1E

Q27673316-1FA4404B-E29F-4F34-8C75-78CF86C408E3

Q27673316-A8D25D01-C3F2-40D2-94A9-933C2FBDF011

Q27673316-DB5B13CB-944A-4F09-B83E-034AC6E3D073

Q27673316-ED17555C-FB41-44E7-B459-1C63C461DA5A

Q27673316-FEE2EB06-6541-4D80-8612-C4EB89AD442A

P2860

Q27673316-039A68C8-F1F9-4ED5-9445-3020AB0BAF30

Q27673316-0620E5D3-5ECB-4666-B177-41346E77407A

Q27673316-081D4CE6-639D-4D60-A580-91074854C682

Q27673316-0B8604C3-87AE-4F68-B4ED-702DEDAD9817

Q27673316-1EB542BA-CC8A-4000-AC94-5F8E229837DE

Q27673316-285011A6-9646-41CA-A739-AF8FE111806C

Q27673316-29302C13-66FF-4C38-863D-7F96C8455028

Q27673316-2E1FDC51-6629-4EE3-A69B-CF029F3F2650

Q27673316-31C58EE4-C515-4472-8C01-541999C61E56

Q27673316-32A24F9A-D7C1-432E-9E0E-FD024B681253

P304

Q27673316-EA4EEB72-4E7A-4799-AE0E-DC8A92FE5AA5

P31

Q27673316-45ACE2AF-859E-4438-A595-3A4B2BEABF22

P3181

Q27673316-0FA3EE73-AAEB-485B-A582-62668F3993F1

P356

Q27673316-66B44156-2D94-4852-9AFF-47AE182028F8

P433

Q27673316-EEF706CD-F745-4B9A-9734-DE0E4B0E97A8

P478

Q27673316-C2260705-5C4E-43CF-AA74-ECE85B87DC00

P50

Q27673316-08ED7B46-0B0F-472E-8305-F2871C8B08C3

Q27673316-4CD09C52-A896-47BB-87D5-4370C5DFB353

Q27673316-72B903E9-9C5B-447B-9E19-C6AAD0FC8832

P577

Q27673316-F674EBF9-AA2E-45DA-9D3C-F7C131C7478A

P5875

Q27673316-047953F7-3D37-493F-B35F-45361C2D5745

P698

Q27673316-5B7B2E41-E96E-4A79-93A6-3EEBE1BD0C28

P921

Q27673316-4239D1FB-31F0-435D-95A2-EF05D2E7C039

P932

Q27673316-AE7A45AE-8432-4050-B8F5-722EC8F54F20

P3181

P356

P1433

EMBO Molecular Medicine

P1476

Towards a new tuberculosis drug: pyridomycin - nature's isoniazid

@en

P2093

Florence Pojer

http://www.w3.org/2001/XMLSchema#string

Karl-Heinz Altmann

http://www.w3.org/2001/XMLSchema#string

Raju Mukherjee

http://www.w3.org/2001/XMLSchema#string

Sophie Magnet

http://www.w3.org/2001/XMLSchema#string

Stefanie Boy-Röttger

http://www.w3.org/2001/XMLSchema#string

Stewart T Cole

http://www.w3.org/2001/XMLSchema#string

Swapna Uplekar

http://www.w3.org/2001/XMLSchema#string

P2860

Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance

Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate

Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis

Triclosan Derivatives: Towards Potent Inhibitors of Drug-Sensitive and Drug-ResistantMycobacterium tuberculosis

Phosphorylation of InhA inhibits mycolic acid biosynthesis and growth of Mycobacterium tuberculosis

Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis

A mechanism of drug action revealed by structural studies of enoyl reductase

AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR

P304

1032-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1788514

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/EMMM.201201689

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Ruben Hartkoorn

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230871600

http://www.w3.org/2001/XMLSchema#string

P698

22987724

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

3491834

http://www.w3.org/2001/XMLSchema#string